Form 4 for GLUE Monte Rosa Therapeutics, Inc.
Accepted 2026-07-01 16:57:48 ET · period of report 2026-06-30 · accession 0001193125-26-292767 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-01 16:57 | 2026-06-30 | GLUE | Janku Filip | Chief Medical Off | M - OptEx | $13.41 | +5,407 | 66.0K | +9% | +$72.5K |
| DT | 2026-07-01 16:57 | 2026-06-30 | GLUE | Janku Filip | Chief Medical Off | S - Sale+OE | $24.50 | -5,407 | 60.6K | -8% | -$132.5K |
| DT | 2026-07-01 16:57 | 2026-06-30 | GLUE | Janku Filip | Chief Medical Off | M - OptEx | $0.00 | -5,407 | 81.1K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | M | A | 5,407 | $13.41 | 66,019 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. (F2) Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026. |
| 2 | Common | Common Stock | 2026-06-30 | S | D | 5,407 | $24.50 | 60,612 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 5,407 | $0.00 | 81,093 | D | $13.41 · — to 2032-02-29 | 5,407 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. (F3) The shares underlying this option are fully vested and exercisable. |